Pallas Health vs Willow: Clinician-picked pens vs oral GLP-1 support
Quick verdict: Pallas Health vs Willow
Pallas Health is a 100% online program where a US-licensed clinician chooses between FDA-approved injectable brand GLP-1s or compounded semaglutide or tirzepatide, with compounded semaglutide starting at $139 first month. Willow is a telehealth-first oral GLP-1 program that emphasizes progress tracking and structured follow-up support. If you want clinician selection between brand injectable pens and compounded injections choose Pallas Health; if you want an oral GLP-1 journey with tracking tools choose Willow.
How they differ: medication options and formats
Pallas Health offers both FDA-approved brand-name injectable GLP-1s including Wegovy, Ozempic, Zepbound and Mounjaro and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. Willow positions an oral GLP-1 program. Medication-specific approval status must be confirmed for Willow. Compounded medications when offered are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Explore Pallas medication options
Price structure and billing
Pallas publishes specific cash-pay figures for both compounded and brand plans. Compounded semaglutide is $139 for the first month, then $597 every 12 weeks, a $199 per month average; compounded tirzepatide is $179 first month, then $897 every 12 weeks, a $299 per month average. Brand-name medications are cash-pay and billed monthly with listed prices such as Wegovy at $1,349 per month on the captured page. Pallas is cash-pay only and does not bill insurance. Willow captured a starting price of $299 in the source, and the site notes higher monthly entry pricing for some plans, but detailed billing and shipping information was not verified on the captured page.
Care model, follow-up and access
Pallas is 100% online and asynchronous in most states, noting that 43 of 50 states need no video visit and that a video visit is required in seven states plus Washington, D.C. Provider care, check-ins and messaging are included in Pallas plan pricing with no membership fee. Pallas says eligibility is determined by a US-licensed clinician and care-team hours are weekdays 9 AM to 5 PM ET. Willow is described as telehealth-first with a licensed telehealth team, progress tracking tools and follow-up consultations, and it emphasizes structured digital follow-up to convert GLP-1 efficacy into sustainable outcomes. Treatment at Willow is available only when a licensed clinician determines it is medically appropriate.
Regulatory and quality notes
Both providers include language about compounded products: Pallas states compounded medications are not FDA-approved and are prepared by US-licensed compounding pharmacies; the medication may differ in appearance from images. Willow notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Pallas also carries LegitScript Healthcare Merchant Certification on the captured page and publishes medical team and clinical disclosures.
Comparison table
| Criteria | Pallas Health | Willow |
|---|---|---|
| Primary medication formats | FDA-approved injectable brands and compounded injectable semaglutide or tirzepatide | Oral GLP-1 program |
| Starting price (captured) | Compounded semaglutide $139 first month; then $597/12 weeks ($199/mo avg) | Captured starting price $299; full billing not verified |
| Care model | 100% online, asynchronous in most states; clinician review included | Telehealth-first with licensed team, tracking and follow-up |
| Follow-up & tools | Ongoing check-ins and care-team messaging included in plan price | Progress tracking tools and follow-up consultations emphasized |
| Insurance billing | Cash-pay only; does not bill insurance | Not specified on captured page |
| Compounded medication note | Compounded meds are not FDA-approved; prepared by US compounding pharmacies | Compounded meds when offered are not FDA-approved; approval status must be confirmed |
Other practical differences
Pallas charges compounded plans by medication rather than by milligram so titration does not raise the plan price, and plans renew every 12 weeks for compounded options, which may affect cancellation timing. Pallas offers free expedited and discreet shipping on captured pages and a self-serve portal and free companion app. Willow emphasizes a structured behavioral support model and simple digital workflow; captured landing-page evidence for shipping, fees and expanded FAQs was not available.
Conclusion: Pallas Health vs Willow
In a direct comparison, Pallas Health is centered on clinician choice between injectable brand GLP-1 pens and compounded injectable options with explicit cash-pay pricing and an asynchronous online model. Willow centers on an oral GLP-1 program with progress tracking, structured follow-up and telehealth-first workflows. Choose based only on which model matches your priorities.
Choose Pallas Health if you want a clinician to pick between FDA-approved injectable brand pens and a US-compounded injectable option, explicit captured starting prices for compounded plans, included provider care and asynchronous online access. Choose Willow if you want an oral GLP-1 program with progress tracking and structured follow-up from a licensed telehealth team.